Safety and immunogenicity of an AS03-adjuvanted SARS-CoV-2 recombinant protein vaccine (CoV2 preS dTM) in healthy adults: interim findings from a phase 2, randomised, dose-finding, multicentre study.

ABSTRACT:

SUBMITTER: Sridhar S 

PROVIDER: S-EPMC8789245 | biostudies-literature | 2022 May

REPOSITORIES: biostudies-literature